{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:26:30Z","timestamp":1788546390508,"version":"build-2803163510"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Stevens\u2013Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening mucocutaneous reactions with high mortality. The A severity-of-illness score for toxic epidermal necrolysis (SCORTEN) scale remains the principal tool for early estimation of in-hospital death risk. The study was aimed to assess the predictive value of individual SCORTEN components for hospital mortality in a real-world Moscow cohort and to characterize demographic and etiologic factors associated with outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 150 adult patients (median age 50 years; IQR: 31\u201363; 59.3% female) admitted with SJS (45.3%) or TEN (54.7%) between 2019 and 2024. SCORTEN parameters were recorded within 24 h of admission. Univariate analyses (chi-square or Fisher's exact test) identified associations between each SCORTEN variable and in-hospital death. Kaplan\u2013Meier survival curves and Cox proportional-hazards models quantified time-to-event outcomes and adjusted hazard ratios (HR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall mortality was 18.7% (\n                      <jats:italic>n<\/jats:italic>\n                      = 28). In univariate analysis, age &amp;gt;40 years (OR: 3.53;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.01), associated malignancy (OR: 3.35;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.03), heart rate &amp;gt; 120 bpm (OR: 9.42;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001), serum urea &amp;gt;28 mg\/dL (OR: 14.25;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001), and bicarbonate &amp;lt;20 mmol\/L (OR: 7.25;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001) were significantly linked to death. In multivariate Cox regression, malignancy (HR: 3.57;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.05), urea &amp;gt; 28 mg\/dL (HR: 4.33;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.03), and tachycardia (HR: 2.77;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.04) remained independent predictors. Initial epidermal detachment, serum glucose, and age did not retain significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings support continued use of SCORTEN while highlighting the need to recalibrate or augment its parameters\u2014particularly renal and oncologic variables\u2014to improve risk stratification in current therapeutic contexts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1735242","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:39:04Z","timestamp":1768196344000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Predictive value of a severity-of-illness score for toxic epidermal necrolysis (SCORTEN) factors for in-hospital mortality in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Ekaterina","family":"Nikitina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dushkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Streltsov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Andreev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Kruglova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulyana","family":"Markina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Lebedkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Fedorovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Karaulov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryana","family":"Lysenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Fomina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/2042098611404094","article-title":"Systematic review of treatments for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality","volume":"2","author":"Roujeau","year":"2011","journal-title":"Ther Adv Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1213889","DOI":"10.3389\/fmed.2023.1213889","article-title":"Updates in SJS\/TEN: collaboration, innovation, and community","volume":"10","author":"Marks","year":"2023","journal-title":"Front Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2133.1956.tb12766.x","article-title":"Toxic epidermal necrolysis: an eruption resembling scalding of the skin","volume":"68","author":"LYELL","year":"1956","journal-title":"Br J Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens\u2013Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1440-0960.2011.00862.x","article-title":"The management of toxic epidermal necrolysis","volume":"53","author":"Fernando","year":"2012","journal-title":"Australas J Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1529-8019.2009.01260.x","article-title":"Clinical risk management of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis spectrum","volume":"22","author":"Knowles","year":"2009","journal-title":"Dermatol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2165\/11532540-000000000-00000","article-title":"New Insights in Toxic Epidermal Necrolysis (Lyell's Syndrome)","volume":"33","author":"Paquet","year":"2010","journal-title":"Drug Saf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"CD013130","DOI":"10.1002\/14651858.CD013130.pub2","article-title":"Systemic interventions for treatment of Stevens\u2013Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome","volume":"3","author":"Jacobsen","year":"2022","journal-title":"Cochr Database Syst Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.bjps.2004.12.007","article-title":"Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report","volume":"58","author":"Lissia","year":"2005","journal-title":"Br J Plast Surg."},{"key":"B10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2165\/00128071-200405030-00003","article-title":"Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease","volume":"5","author":"Ruetter","year":"2004","journal-title":"Am J Clin Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s00403-025-04214-x","article-title":"Adalimumab combination with corticosteroid therapy for Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"317","author":"Liu","year":"2025","journal-title":"Arch Dermatol Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1342898","DOI":"10.3389\/fimmu.2024.1342898","article-title":"Etanercept treatment for pediatric toxic epidermal necrolysis induced by deflazacort: a case report and literature review","volume":"15","author":"Jeong","year":"2024","journal-title":"Front Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1421684","DOI":"10.3389\/fimmu.2024.1421684","article-title":"Tumor necrosis factor inhibitors enhance corticosteroid therapy for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis linked to immune checkpoint inhibitors: a prospective study","volume":"15","author":"He","year":"2024","journal-title":"Front Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12911-022-02013-2","article-title":"Accuracy of SCORTEN in predicting mortality in toxic epidermal necrolysis","volume":"22","author":"Stru\u017cyna","year":"2022","journal-title":"BMC Med Inform Decis Mak"},{"key":"B16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/j.1468-3083.2012.04502.x","article-title":"and impaired renal function related to mortality of toxic epidermal necrolysis syndrome patients in the Asian population","volume":"27","author":"Hu","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/BCR.0b013e31820aafbc","article-title":"Evaluation of SCORTEN on a cohort of patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study","volume":"32","author":"Sekula","year":"2011","journal-title":"J Burn Care Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamadermatol.2019.0998","article-title":"Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens\u2013Johnson Syndrome\/toxic epidermal necrolysis-ABCD-10","volume":"155","author":"Noe","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/1346-8138.15490","article-title":"Accuracy of SCORTEN and ABCD-10 to predict mortality and the influence of renal function in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"47","author":"Torres-Navarro","year":"2020","journal-title":"J Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jamadermatol.2020.3654","article-title":"Assessment and comparison of performance of ABCD-10 and SCORTEN in prognostication of epidermal necrolysis","volume":"156","author":"Koh","year":"2020","journal-title":"JAMA Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/jdv.16685","article-title":"Systemic therapies for Stevens\u2013Johnson Syndrome and Toxic Epidermal Necrolysis: a SCORTEN-based systematic review and meta-analysis","volume":"35","author":"Torres-Navarro","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamadermatol.2018.5605","article-title":"Development and validation of a risk prediction model for inpatient mortality in SJS\/TEN","volume":"155","author":"Noe","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12911-022-02013-2","article-title":"Accuracy of SCORTEN in predicting mortality in toxic epidermal necrolysis","volume":"22","author":"Stru\u017cyna","year":"2022","journal-title":"BMC Med Inform Decis Mak"},{"key":"B25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens\u2013Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3892\/etm.2015.2549","article-title":"Clinical characteristics and treatment outcome of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"10","author":"Chantaphakul","year":"2015","journal-title":"Exp Ther Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/ijd.15586","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in a referral center in Taiwan","volume":"60","author":"Hsu","year":"2021","journal-title":"Int J Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1001\/jamadermatol.2021.3154","article-title":"Assessment of treatment approaches and outcomes in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"157","author":"Kridin","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4103\/idoj.idoj_530_21","article-title":"The clinical characteristics, putative drugs, and optimal management of 62 patients with Stevens\u2013Johnson syndrome and\/or toxic epidermal necrolysis: a retrospective observational study","volume":"13","author":"Manvi","year":"2022","journal-title":"Indian Dermatol Online J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1001\/jamadermatol.2021.5119","article-title":"Improvement of mortality prognostication in patients with epidermal necrolysis","volume":"158","author":"Koh","year":"2022","journal-title":"JAMA Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens\u2013Johnson syndrome","volume":"5","author":"Harr","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e0165933","DOI":"10.1371\/journal.pone.0165933","article-title":"Incidence of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using national health insurance database in Korea","volume":"11","author":"Yang","year":"2016","journal-title":"PLoS ONE"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/bjd.14052","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in patients with malignancies","volume":"173","author":"Wu","year":"2015","journal-title":"Br J Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3233\/CH-189111","article-title":"Blood urea nitrogen (BUN) independently predicts mortality in critically ill patients admitted to ICU: a multicenter study","volume":"69","author":"Wernly","year":"2018","journal-title":"Clin Hemorheol Microcirc."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1111\/jdv.16339","article-title":"Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN)","volume":"34","author":"Kuijper","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/TME.0000000000000225","article-title":"A review of the management of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"41","author":"Woolum","year":"2019","journal-title":"Adv Emerg Nurs J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-020-0145-5","article-title":"Burn injury","volume":"6","author":"Jeschke","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"B38","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/BCR.0b013e31825aea8d","article-title":"The Acute Kidney Injury Network (AKIN) criteria applied in burns","volume":"33","author":"Chung","year":"2012","journal-title":"J Burn Care Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure\u2014definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care."},{"key":"B40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1744-9987.2009.00800.x","article-title":"Beneficial therapeutic effect of plasmapheresis after unsuccessful treatment with corticosteroids in two patients with severe toxic epidermal necrolysis","volume":"14","author":"Szczeklik","year":"2010","journal-title":"Ther Apher Dial."},{"key":"B41","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.24748.1","article-title":"Recent advances in managing and understanding Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Hasegawa","year":"2020","journal-title":"F1000Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1097\/CM9.0000000000003250","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: Updates in pathophysiology and management","volume":"137","author":"Hasegawa","year":"2024","journal-title":"Chin Med J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/jbcr\/irx016","article-title":"How Does SCORTEN Score?","volume":"39","author":"Zavala","year":"2018","journal-title":"J Burn Care Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"258","DOI":"10.4103\/idoj.IDOJ_437_20","article-title":"Factors predicting the outcome of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a 5-year retrospective study","volume":"12","author":"Thakur","year":"2021","journal-title":"Indian Dermatol Online J."},{"key":"B45","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12911-022-02013-2","article-title":"Accuracy of SCORTEN in predicting mortality in toxic epidermal necrolysis","volume":"22","author":"Stru\u017cyna","year":"2022","journal-title":"BMC Med Inform Decis Mak."},{"key":"B46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4103\/0378-6323.38405","article-title":"Does it need modification?","volume":"74","author":"Vaishampayan","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/jdv.16685","article-title":"Systemic therapies for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a SCORTEN-based systematic review and meta-analysis","volume":"35","author":"Torres-Navarro","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1038\/s41598-019-38892-1","article-title":"Short-term and long-term effects of low serum bicarbonate level at admission in hospitalised patients","volume":"9","author":"Lim","year":"2019","journal-title":"Sci Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1177\/0885066610390466","article-title":"Serum bicarbonate as a marker to predict mortality in toxic epidermal necrolysis","volume":"26","author":"Yeong","year":"2011","journal-title":"J Intensive Care Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/BCR.0b013e31820aafbc","article-title":"Evaluation of SCORTEN on a cohort of patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study","volume":"32","author":"Sekula","year":"2011","journal-title":"J Burn Care Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/ijd.17584","article-title":"External validation study of Re-SCORTEN in patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","author":"Westmeijer","year":"2024","journal-title":"Int J Dermatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.alit.2020.11.004","article-title":"Mortality and risk factors on admission in toxic epidermal necrolysis: a cohort study of 59 patients","volume":"70","author":"Watanabe","year":"2021","journal-title":"Allergol Int."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1735242\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:39:10Z","timestamp":1768196350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1735242\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":52,"alternative-id":["10.3389\/fmed.2025.1735242"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1735242","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1735242"}}